TY - JOUR T1 - Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years JF - Evidence Based Medicine JO - Evid Based Med SP - 9 LP - 10 DO - 10.1136/ebm.14.1.9 VL - 14 IS - 1 A2 - , Y1 - 2009/02/01 UR - http://ebm.bmj.com/content/14/1/9.abstract N2 - R R HolmanDr R R Holman, Diabetic Trials Unit, Oxford, UK; rury.holman@dtu.ox.ac.ukDesign:randomised controlled trial (UK Prospective Diabetes Study [UKPDS]). Current Controlled Trials ISRCTN75451837.Allocation:{concealed}*.†Blinding:blinded (outcome adjudication committee).†Setting:23 centres in the UK.Patients:4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included recent myocardial infarction, current angina or heart failure, and >1 major vascular event.Intervention:intensive glucose control with a sulfonylurea or insulin (n = 2729) or conventional therapy with diet (n = 1138). Overweight patients were also allocated to a third group involving intensive therapy with metformin (n = 342).Outcomes:7 composite outcomes (any diabetes-related end point, diabetes-related death, death from any cause, myocardial infarction, stroke, peripheral vascular disease, and microvascular disease).Follow-up period:median 9 years after the end of the trial, 17 years total.Patient follow-up:80–97% (intention-to-treat analysis). … ER -